SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is facing significant downward volatility as the market digests broader semiconductor sector rotation and heavy institutional selling, despite the company reporting record revenue and strong AI-driven guidance. While some investors view the pullback as a buying opportunity given the company's central role in the AI infrastructure buildout, the community remains divided, with active debates centered on whether recent price action reflects a structural correction in the AI bubble or a temporary liquidity-driven hunt.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is rallying as institutional investors and high volume suggest a significant accumulation phase, leading the community to discuss a potential short squeeze as the stock breaks through key resistance levels. Traders are increasingly bullish, pointing to the company's strong cash position, profitability, and leadership in the agentic AI and orchestration sector as primary drivers for the sustained upward momentum.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors digest positive commentary regarding manufacturing progress and FDA alignment for its lead candidate, CAN-2409, ahead of a planned BLA submission. The community is actively discussing strong institutional ownership and anticipation for upcoming clinical data presentations at the ASTRO meeting.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Georgetown, TX.

TSS Inc

TSS Inc. is facing intense downward pressure following a weak earnings report that disappointed investors with declining revenue, despite some community interest in their pivot toward higher-margin systems integration and long-term data center infrastructure. While bulls are pinning hopes on future rack integration growth and new facility expansions, the community remains deeply divided, with many actively discussing the lack of growth visibility and management's perceived failure to capitalize on the AI infrastructure boom.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is experiencing significant downward pressure as investors express frustration over a prolonged slide and lack of direct communication from management regarding integration progress following recent acquisitions. Despite bearish sentiment, the community remains divided, with long-term supporters pointing to institutional accumulation and the CEO's track record as reasons to maintain positions while others warn of continued volatility tied to macro headwinds and ongoing selling pressure.

Workday, Inc. engages in the development of enterprise cloud applications for finance and human resources. The firm delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. It operates through the Cloud Applications segment. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday stock is trending following reports that private equity firm Silver Lake is in early-stage talks to acquire the company, triggering significant market volatility and multiple trading halts. While the market is buzzing over the potential for a massive leveraged buyout, investors remain divided, with some questioning the feasibility of the rumored valuation and others debating whether this signals a sector-wide recovery for software companies.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) is experiencing significant upward momentum as investors speculate on the potential passage of the Clarity Act and celebrate recent regulatory wins, including the company's federal trust bank charter. The community is actively tracking the stock's institutional accumulation, with many discussing its long-term potential as essential financial infrastructure for AI-driven payments and real-world assets.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings is facing mixed sentiment as investors weigh strong customer growth and recent strategic expansion against concerns over CFO turnover and broader regional credit risks. While some community members view the current price action as an accumulation opportunity, others are exercising caution ahead of upcoming earnings and monitoring the impact of new leadership on the company's long-term international expansion.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing significant volatility and intense community debate as shareholders react to an accelerated lockup expiration, sparking fears of a potential sell-off. Investors remain polarized, with bulls pointing to the fund's exposure to high-profile AI and space companies like Anthropic and SpaceX as long-term catalysts, while bears warn that the stock continues to trade at a substantial premium to its net asset value.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

SPRY is trending as investors monitor ongoing institutional positioning and short interest dynamics while awaiting news regarding CVS Caremark formulary inclusion. The community remains divided, with debates centered on whether recent volatility reflects a buying opportunity ahead of potential catalysts or broader concerns over the company's commercial execution and competitive landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX PR Newswire NEW YORK, Aug...

TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract

TMDX's Q2 revenue beat and raised outlook are overshadowed by earnings miss, declining margins and sharply higher operating costs.

TransMedics (TMDX) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

TransMedics (TMDX) Q2 Earnings Lag Estimates

TransMedics (TMDX) delivered earnings and revenue surprises of -12.00% and +3.14%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

TransMedics Reports Second Quarter 2026 Financial Results

TransMedics Reports Second Quarter 2026 Financial Results TransMedics Reports Second Quarter 2026 Financial Results PR Newswire ANDOVER, Mass., Aug. 4, 2026 ANDOVER, Mass., Aug. 4, 2026 /PRNewswire/ --TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is...

TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. TMDX

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX).If you currently own shares of TransMedics Group stock, please visit the firms website at...

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire ANDOVER, Mass., Aug. 3, 2026 ANDOVER, Mass., Aug. 3, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a...

Earnings Preview: RxSight, Inc. (RXST) Q2 Earnings Expected to Decline

RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference

TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference PR Newswire ANDOVER, Mass., July 28, 2026 ANDOVER, Mass., July 28, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX...

Analysts Estimate TransMedics (TMDX) to Report a Decline in Earnings: What to Look Out for

TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

$TMDX Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.42 down -59.22% YoY
• Reported revenue of $189.95M up 20.70% YoY

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Transmedics Group Inc

TMDX Stock Rallies As Analyst Sees 77% Upside  — Here’s Why  

Equity

Bullish Sentiment

Buying - this is temporary noise

Holding existing position

Selling / Trimming / Shorting

Watching from the sidelines

$TMDX is sliding after Stifel flagged a surge in "dry runs.". TransMedics investors are divided: is this a temporary operational blip or a structural crack in the growth story? Cast your vote below.

$TMDX sliding on &quot;dry run&quot; concerns - are you buying this dip?

Stocktwits

 sliding on "dry run" concerns - are you buying this dip?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	$0.30	--	--	N/A
Q2 '26	$0.44	$0.44	-1.09%	MISSED
Q1 '26	$0.60	$0.30	-49.84%	MISSED
Q4 '25	$0.44	$2.62	500.36%	BEAT
Q3 '25	$0.36	$0.66	83.06%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings